Please assess the completion status of the following clinical trial:

Trial Title: Study in Adolescents/Adults to Evaluate the Persistence up to 3.5 Yrs of GSK Biologicals Meningococcal Vaccine 134612

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects who the investigator believes that they and/or their parents/guardians can and will comply with the requirements of the protocol.~* A male or female, who was primed with meningococcal vaccine 134612 or Mencevax™ ACWY in the primary vaccination study 18 months before the first persistence assessment and who completed that study.~* Written informed consent obtained from the subject/ from the parent or guardians of the subject.~* Written informed assent obtained from the subject, as applicable, at the time of study entry.~Exclusion Criteria:~• Administration of a meningococcal polysaccharide or a meningococcal polysaccharide conjugate vaccine since the last visit of the primary vaccination study.

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 19 Years
- Healthy Volunteers: t

Study Arms:
- Group A (Type: EXPERIMENTAL): Subjects previously primed with meningococcal vaccine 134612.
- Group B (Type: ACTIVE_COMPARATOR): Subjects previously primed with Mencevax™ ACWY.

Based on this trial design, predict the completion outcome and termination type (if applicable).